An initial safety study of Gedatolisib plus PTK7-ADC for metastatic triple-negative breast cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: breast cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria
Metastatic Triple-negative Breast Cancer
Willingness to undergo tumor biopsy
Patients must have received at least 1 prior chemotherapy regimen for metastatic disease
Exclusion Criteria
Previous treatment with mTOR inhibitor
Untreated brain metastases

Recruitment Status

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at or by phone at (888) 264-0005.